查看“Rocatinlimab”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[罗卡替单抗]]([[Rocatinlimab]])</strong>，研发代码为<strong>[[AMG451]]</strong>或<strong>[[KHK4083]]</strong>，是一种全人源化、无岩藻糖修饰的单克隆抗体，特异性靶向<strong>[[OX40]]([[CD134]])</strong>受体。该受体主要表达于活化的<strong>[[效应T细胞]]</strong>表面。与传统的细胞因子阻断剂不同，[[Rocatinlimab]]通过双重机制发挥作用：既能阻断OX40L介导的促炎信号，又能选择性耗竭致病性[[OX40]]高表达的T细胞。在2026年的皮肤病学前沿中，[[Rocatinlimab]]被认为具有“疾病修饰”潜力，在治疗<strong>[[中重度特应性皮炎]]</strong>(AD)中展现出停药后疗效持久维持的独特临床优势。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Rocatinlimab</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">OX40 Targeted mAb (AMG451)·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">mAb targeting CD134 on T-cells</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点基因：[[TNFRSF4]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7293</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P43489</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">全人源化IgG1单抗</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[安进]]•[[协和麒麟]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">皮下注射([[SC]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键试验</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[ROCKET]]系列研究</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th>
                    <td style="padding: 12px; color: #1e40af;">自身免疫病长效免疫重置药</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：选择性T细胞耗竭与免疫重置</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[Rocatinlimab]]通过其独特的结构设计，实现了对免疫系统的精准干预。2026年的分子免疫学共识将其机制总结为：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>OX40 信号阻断：</strong>
            通过特异性结合效应T细胞表面的[[OX40]]，阻断其与配体[[OX40L]]的结合，从而切断T细胞增殖与产生[[IL-4]]、[[IL-13]]等细胞因子的生存信号。</li>
        <li style="margin-bottom: 12px;"><strong>无岩藻糖修饰增强的ADCC：</strong>
            [[Rocatinlimab]]采用了<strong>[[POTELLIGENT]]</strong>技术，删除了[[Fc]]段的岩藻糖残基。这极大地增强了其与NK细胞上<strong>[[FcγRIIIa]]</strong>的亲和力，从而通过<strong>[[抗体依赖性细胞介导的细胞毒性]]([[ADCC]])</strong>精准耗竭致病性[[OX40]]高表达的效应T细胞。</li>
        <li style="margin-bottom: 12px;"><strong>疾病修饰效应：</strong>
            2026年的长期随访数据证实，这种对活化T细胞的物理清除能显著减少<strong>[[组织驻留记忆T细胞]]([[Trm]])</strong>，从而在停药后实现皮肤症状的长期廓清，实现免疫稳态的重塑。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床循证与全球布局</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026临床证据(试验名称)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[特应性皮炎]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[ROCKET-Horizon]]：中重度成人AD，EASI-75缓解持久。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>停药后不反弹</strong>。改变了“需终身用药”的传统观念。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[哮喘]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">IIb期研究显示能有效减少嗜酸性粒细胞介导的急性发作。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">拓展[[Th2]]通路靶向范围。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[系统性红斑狼疮]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">针对[[T细胞]]亚群异常活化的早期探索。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">作为<strong>[[疾病修饰药]]</strong>的潜力开发。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：精准给药与安全性管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[Rocatinlimab]]在2026年的临床应用中，侧重于其独特的药效动力学管理：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>诱导与维持方案：</strong>起始阶段采取高频给药以迅速清空致病T细胞池，随后转入每4-8周一次的低频维持。2026共识探讨了根据患者[[OX40+]]T细胞比例进行<strong>[[个体化停药]]</strong>的可能性。</li>
        <li style="margin-bottom: 12px;"><strong>发热反应监控：</strong>由于ADCC效应引起的细胞裂解，部分患者首次给药后可能出现轻微一过性发热。2026版指南建议首次注射时可配合非甾体抗炎药。</li>
        <li style="margin-bottom: 12px;"><strong>预防性疫苗接种：</strong>由于其对记忆T细胞的影响，2026临床规范要求患者在启动[[Rocatinlimab]]治疗前应完成必要的灭活疫苗接种。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[OX40]]([[TNFRSF4]])：</strong> 共刺激受体，特应性皮炎皮损中T细胞的核心标记。</li>
            <li style="margin-bottom: 8px;"><strong>[[ADCC]]([[抗体依赖性细胞介导的细胞毒性]])：</strong> [[Rocatinlimab]]清除病理细胞的核心杀伤手段。</li>
            <li style="margin-bottom: 8px;"><strong>[[Amlitelimab]]：</strong> 赛诺菲开发的靶向[[OX40L]]的竞争产品，侧重于配体中和。</li>
            <li style="margin-bottom: 8px;"><strong>[[组织驻留记忆T细胞]]([[Trm]])：</strong> 导致皮炎反复发作的根源，是[[Rocatinlimab]]的终极打击目标。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Guttman-Yassky E,et al.(2023/2025Revision).</strong> <em>Rocatinlimab for the treatment of moderate-to-severe Atopic Dermatitis:A Phase 2b randomized clinical trial.</em> <strong>[[The Lancet]]</strong>.<br>
            <span style="color: #475569;">[学术点评]：该研究首次证明了针对[[OX40]]的抗体在停药后仍能维持长达20周以上的显著疗效。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Silverberg JI,et al.(2024/2026Update).</strong> <em>Long-term safety and efficacy of Rocatinlimab in atopic dermatitis:Two-year results from the ROCKET trial.</em> <strong>[[Journal of the American Academy of Dermatology]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[学术点评]：2026年的长效分析确立了[[罗卡替单抗]]在重塑皮肤微环境平衡中的基石地位。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            罗卡替单抗 (Rocatinlimab) · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[OX40]]•[[OX40L]]•[[IL-4]]•[[IL-13]]•[[FcγRIIIa]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗领域</td>
                <td style="padding: 10px 15px; color: #334155;">[[特应性皮炎]]•[[哮喘]]•[[斑秃]]•[[SLE]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心技术</td>
                <td style="padding: 10px 15px; color: #334155;">[[无岩藻糖修饰]]•[[POTELLIGENT]]•[[全人源单抗]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">临床优势</td>
                <td style="padding: 10px 15px; color: #334155;">[[停药后持续缓解]]•[[靶向效应T细胞耗竭]]•[[长效免疫调节]]</td>
            </tr>
        </table>
    </div>

</div>